<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654314</url>
  </required_header>
  <id_info>
    <org_study_id>1601017038</org_study_id>
    <nct_id>NCT02654314</nct_id>
  </id_info>
  <brief_title>Prevention of Delirium in Inpatients Utilizing Melatonin</brief_title>
  <acronym>PODIUM</acronym>
  <official_title>Prevention of Delirium in Inpatients Utilizing Melatonin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double blind randomized controlled trial investigating melatonin, 5mg, compared to placebo,
      given to patients at least 65 years old, admitted to the hospital on a general medical floor,
      to prevent delirium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized double blind controlled trial, designed to evaluate the
      efficacy of melatonin in decreasing the incidence of delirium in elderly hospitalized adults
      compared to a placebo capsule. The study will be conducted on 4 general Internal Medicine
      inpatient floors at Yale-New Haven Hospital, St. Raphael's campus.

      Within 24 hours of admission to the floor, study subjects will be approached by a member of
      the research team, and asked for informed consent. Patients that consent to participate will
      be randomized to either the treatment or the placebo arm. Each subject will be administered a
      capsule containing either placebo or 5 mg melatonin each evening at 9 p.m. The capsules will
      be prepared and administered by the Yale-New haven Hospital Investigational Drug Service. The
      capsules will be administered nightly until discharge or a maximum of 2 weeks, if the
      hospitalization is prolonged.

      Subjects will be assessed twice daily by the floor nurses for evidence of delirium using the
      Short CAM (Confusion Assessment Method), which is a validated clinical tool for identifying
      delirium, and the current standard of practice tool for the diagnosis of delirium.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of resources to complete the study. Descriptive statistics for the outcome measures
    collected are provided.
  </why_stopped>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">November 3, 2017</completion_date>
  <primary_completion_date type="Actual">November 3, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delirium</measure>
    <time_frame>length of hospitalization, not to exceed 14 days</time_frame>
    <description>Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>from day of admission to completion of acute care, not to exceed 30 days</time_frame>
    <description>Length of stay is defined as the total time hospitalized for the acute illness (in days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Utilizing Restraints</measure>
    <time_frame>length of hospitalization, not to exceed 14 days</time_frame>
    <description>Days utilizing restraints is defined as the number of days restraints were applied because of delirium in the first 14 days of hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Delirium Anti-psychotic Drug Doses Utilized for Delirium During the First 14 Days of Hospitalization.</measure>
    <time_frame>length of hospitalization, not to exceed 14 days</time_frame>
    <description>Number of delirium anti-psychotic drug doses given for symptoms of delirium. Presented are the number of doses per days of hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg Melatonin nightly, beginning within 24 hours of admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellulose Microcrystylline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blue capsule matching the melatonin arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <arm_group_label>Cellulose Microcrystylline</arm_group_label>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>cellulose microcrystylline</other_name>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient admission to a general internal medicine service

        Exclusion Criteria:

          -  expected lifespan or length of stay â‰¤ 48 hours

          -  Non-English speaking

          -  Already taking melatonin or ramelteon at the time of randomization

          -  Presence of delirium at the time of randomization

          -  Unable to take oral medications

          -  Subject or proxy unable to provide informed consent within 18 hours of invitation or
             24 hours of admission

          -  ALT or AST (Liver function tests) &gt; 3 times the upper limit of normal

          -  Taking warfarin, nifedipine or fluvoxamine

          -  Allergy to melatonin

          -  Unable to recall 3 words after distraction by naming the days of the week backwards
             beginning with Sunday
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen A Atlas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale New Haven Hospital, Saint Raphael Campus</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Inouye SK. Delirium in older persons. N Engl J Med. 2006 Mar 16;354(11):1157-65. Review. Erratum in: N Engl J Med. 2006 Apr 13;354(15):1655.</citation>
    <PMID>16540616</PMID>
  </reference>
  <reference>
    <citation>Miller MO. Evaluation and management of delirium in hospitalized older patients. Am Fam Physician. 2008 Dec 1;78(11):1265-70. Review.</citation>
    <PMID>19069020</PMID>
  </reference>
  <reference>
    <citation>de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry. 2010 Dec;25(12):1201-8. doi: 10.1002/gps.2454. Review.</citation>
    <PMID>21086534</PMID>
  </reference>
  <reference>
    <citation>de Jonghe A, van Munster BC, Goslings JC, Kloen P, van Rees C, Wolvius R, van Velde R, Levi M, de Haan RJ, de Rooij SE; Amsterdam Delirium Study Group. Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. CMAJ. 2014 Oct 7;186(14):E547-56. doi: 10.1503/cmaj.140495. Epub 2014 Sep 2.</citation>
    <PMID>25183726</PMID>
  </reference>
  <reference>
    <citation>Sultan SS. Assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly. Saudi J Anaesth. 2010 Sep;4(3):169-73. doi: 10.4103/1658-354X.71132.</citation>
    <PMID>21189854</PMID>
  </reference>
  <reference>
    <citation>Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2011 Jul;26(7):687-94. doi: 10.1002/gps.2582. Epub 2010 Sep 15. Erratum in: Int J Geriatr Psychiatry. 2014 May;29(5):550.</citation>
    <PMID>20845391</PMID>
  </reference>
  <reference>
    <citation>Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H; DELIRIA-J Group. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014 Apr;71(4):397-403. doi: 10.1001/jamapsychiatry.2013.3320.</citation>
    <PMID>24554232</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <results_first_submitted>January 22, 2019</results_first_submitted>
  <results_first_submitted_qc>January 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2019</results_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention; delirium; in-patients; melatonin,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02654314/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Melatonin</title>
          <description>5 mg Melatonin nightly, beginning within 24 hours of admission
Melatonin</description>
        </group>
        <group group_id="P2">
          <title>Cellulose Microcrystylline</title>
          <description>Blue capsule matching the melatonin arm
Melatonin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin</title>
          <description>5 mg Melatonin nightly, beginning within 24 hours of admission
Melatonin</description>
        </group>
        <group group_id="B2">
          <title>Cellulose Microcrystylline</title>
          <description>Blue capsule matching the melatonin arm
Melatonin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="141"/>
            <count group_id="B3" value="277"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.98" spread="8.53"/>
                    <measurement group_id="B2" value="78.99" spread="8.40"/>
                    <measurement group_id="B3" value="78.49" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Delirium</title>
        <description>Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization.</description>
        <time_frame>length of hospitalization, not to exceed 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>5 mg Melatonin nightly, beginning within 24 hours of admission
Melatonin</description>
          </group>
          <group group_id="O2">
            <title>Cellulose Microcrystylline</title>
            <description>Blue capsule matching the melatonin arm
Melatonin</description>
          </group>
        </group_list>
        <measure>
          <title>Delirium</title>
          <description>Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>Length of stay is defined as the total time hospitalized for the acute illness (in days).</description>
        <time_frame>from day of admission to completion of acute care, not to exceed 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>5 mg Melatonin nightly, beginning within 24 hours of admission
Melatonin</description>
          </group>
          <group group_id="O2">
            <title>Cellulose Microcrystylline</title>
            <description>Blue capsule matching the melatonin arm
Melatonin</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Length of stay is defined as the total time hospitalized for the acute illness (in days).</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="2.91"/>
                    <measurement group_id="O2" value="4.71" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Utilizing Restraints</title>
        <description>Days utilizing restraints is defined as the number of days restraints were applied because of delirium in the first 14 days of hospitalization.</description>
        <time_frame>length of hospitalization, not to exceed 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>5 mg Melatonin nightly, beginning within 24 hours of admission
Melatonin</description>
          </group>
          <group group_id="O2">
            <title>Cellulose Microcrystylline</title>
            <description>Blue capsule matching the melatonin arm
Melatonin</description>
          </group>
        </group_list>
        <measure>
          <title>Days Utilizing Restraints</title>
          <description>Days utilizing restraints is defined as the number of days restraints were applied because of delirium in the first 14 days of hospitalization.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Delirium Anti-psychotic Drug Doses Utilized for Delirium During the First 14 Days of Hospitalization.</title>
        <description>Number of delirium anti-psychotic drug doses given for symptoms of delirium. Presented are the number of doses per days of hospitalization.</description>
        <time_frame>length of hospitalization, not to exceed 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>5 mg Melatonin nightly, beginning within 24 hours of admission
Melatonin</description>
          </group>
          <group group_id="O2">
            <title>Cellulose Microcrystylline</title>
            <description>Blue capsule matching the melatonin arm
Melatonin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Delirium Anti-psychotic Drug Doses Utilized for Delirium During the First 14 Days of Hospitalization.</title>
          <description>Number of delirium anti-psychotic drug doses given for symptoms of delirium. Presented are the number of doses per days of hospitalization.</description>
          <units>number of doses per days of hospitalizat</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the patient's stay in the hospital.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
          <description>5 mg Melatonin nightly, beginning within 24 hours of admission
Melatonin</description>
        </group>
        <group group_id="E2">
          <title>Cellulose Microcrystylline</title>
          <description>Blue capsule matching the melatonin arm
Melatonin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jesse S Reynolds</name_or_title>
      <organization>Yale Center for Analytical Sciences</organization>
      <phone>(203) 785-5445</phone>
      <email>jesse.reynolds@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

